user

A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson's disease Dementia.

被引：0
|
作者：
Pasternak, S. H.
Silviera, C.
Coleman, K.
Finger, E.
Wells, J.
Borrie, M.
Morrow, S.
Zou, G.
Bartha, R.
Macdonald, P.
Jenkins, M. E.
Jog, M.
Tirona, R.
Rupar, C. A.
机构：
来源：
MOVEMENT DISORDERS | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
429
引用
收藏
页码：S189 / S190
页数：2
相关论文
共 50 条
  • [1] A Phase 2 Randomized, Double-blind, Placebo-controlled Trial of Ambroxol as a Disease-modifying Treatment for Parkinson's Disease Dementia
    Pasternak, S.
    Silveira, C.
    Coleman, K.
    Garcia, R.
    Wells, J.
    Borrie, M.
    MacDonald, P.
    Bartha, R.
    Jenkins, M.
    Morrow, S.
    Mendonca, D.
    Zou, G.
    Finger, E.
    Rupar, T.
    Tirona, R.
    Jog, M.
    MOVEMENT DISORDERS, 2023, 38 : S45 - S45
  • [2] Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
    Silveira, C. R. A.
    MacKinley, J.
    Coleman, K.
    Li, Z.
    Finger, E.
    Bartha, R.
    Morrow, S. A.
    Wells, J.
    Borrie, M.
    Tirona, R. G.
    Rupar, C. A.
    Zou, G.
    Hegele, R. A.
    Mahuran, D.
    MacDonald, P.
    Jenkins, M. E.
    Jog, M.
    Pasternak, S. H.
    BMC NEUROLOGY, 2019, 19 (1)
  • [3] Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
    C. R. A. Silveira
    J. MacKinley
    K. Coleman
    Z. Li
    E. Finger
    R. Bartha
    S. A. Morrow
    J. Wells
    M. Borrie
    R. G. Tirona
    C. A. Rupar
    G. Zou
    R. A. Hegele
    D. Mahuran
    P. MacDonald
    M. E. Jenkins
    M. Jog
    S. H. Pasternak
    BMC Neurology, 19
  • [4] Randomized Controlled Trial of Memantine in Dementia Associated with Parkinson's Disease
    Leroi, Iracema
    Overshott, Ross
    Byrne, E. Jane
    Daniel, Emily
    Burns, Alistair
    MOVEMENT DISORDERS, 2009, 24 (08) : 1217 - 1221
  • [5] Caffeine for treatment of Parkinson's disease - A randomized controlled trial
    Postuma, R. B.
    Lang, A. E.
    Munhoz, R. P.
    Charland, K.
    Pelletier, A.
    Moscovich, M.
    Filla, L.
    Zanatta, D. R.
    Romenets, S. Rios
    Altman, R.
    Chuang, R.
    Shah, B.
    MOVEMENT DISORDERS, 2012, 27 : S135 - S135
  • [6] Randomized Placebo-controlled Trial of Memantine for Dementia in Parkinson's Disease
    Marsh, Laura
    Biglan, Kevin M.
    Williams, James R.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 18 (03): : S78 - S79
  • [7] Randomized placebo-controlled trial of memantine for dementia in Parkinson's disease
    Marsh, L.
    Biglan, K.
    Williams, J. R.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S82 - S82
  • [8] Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)
    Postuma, R.
    Anang, J.
    Pelletier, A.
    Moscovich, M.
    Grimes, D.
    Borys, A.
    Furtado, S.
    Munhoz, R.
    Cresswell, S.
    Moro, A.
    Hobson, D.
    Joseph, L.
    Lang, A.
    MOVEMENT DISORDERS, 2017, 32
  • [9] Speech treatment in Parkinson's disease: Randomized controlled trial (RCT)
    Ramig, Lorraine
    Halpern, Angela
    Spielman, Jennifer
    Fox, Cynthia
    Freeman, Katherine
    MOVEMENT DISORDERS, 2018, 33 (11) : 1777 - 1791
  • [10] Caffeine for treatment of Parkinson disease A randomized controlled trial
    Postuma, Ronald B.
    Lang, Anthony E.
    Munhoz, Renato P.
    Charland, Katia
    Pelletier, Amelie
    Moscovich, Mariana
    Filla, Luciane
    Zanatta, Debora
    Romenets, Silvia Rios
    Altman, Robert
    Chuang, Rosa
    Shah, Binit
    NEUROLOGY, 2012, 79 (07) : 651 - 658
12345